We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Surge testing

7 April 2021 By Aimee Donnellan

German diagnostic tester Synlab is planning to float with a mooted $7 bln valuation. A receding pandemic may mean its 38% revenue growth in 2020 isn’t repeated. But the price reflects that, and consumers may well continue to obsess about other aspects of their health.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)